Diabetes Dialogue: Implications of SELECT Trial and Brenzavvy on Cost Plus Drugs

In this episode, hosts take time to break down the implications of two, potentially paradigm-shifting news in the announcement of the addition of bexagliflozin to the Cost Plus Drugs platform and topline data from the landmark SELECT trial.

Video version: https://www.hcplive.com/view/diabetes-dialogue-implications-of-select-trial-and-brenzavvy-on-cost-plus-drugs